- Home
- WRBY vs CNTA Comparison
WRBY vs CNTA Comparison
Compare WRBY & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- CNTA
- Stock Information
- Founded
- WRBY 2010
- CNTA 2020
- Country
- WRBY United States
- CNTA United Kingdom
- Employees
- WRBY N/A
- CNTA N/A
- Industry
- WRBY Ophthalmic Goods
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- CNTA Health Care
- Exchange
- WRBY Nasdaq
- CNTA Nasdaq
- Market Cap
- WRBY 1.9B
- CNTA 2.3B
- IPO Year
- WRBY 2021
- CNTA 2021
- Fundamental
- Price
- WRBY $25.09
- CNTA $17.14
- Analyst Decision
- WRBY Buy
- CNTA Strong Buy
- Analyst Count
- WRBY 10
- CNTA 7
- Target Price
- WRBY $21.00
- CNTA $23.71
- AVG Volume (30 Days)
- WRBY 1.5M
- CNTA 688.3K
- Earning Date
- WRBY 11-07-2024
- CNTA 11-12-2024
- Dividend Yield
- WRBY N/A
- CNTA N/A
- EPS Growth
- WRBY N/A
- CNTA N/A
- EPS
- WRBY N/A
- CNTA N/A
- Revenue
- WRBY $742,527,000.00
- CNTA $6,853,000.00
- Revenue This Year
- WRBY $16.87
- CNTA N/A
- Revenue Next Year
- WRBY $13.10
- CNTA N/A
- P/E Ratio
- WRBY N/A
- CNTA N/A
- Revenue Growth
- WRBY 13.47
- CNTA N/A
- 52 Week Low
- WRBY $11.35
- CNTA $6.65
- 52 Week High
- WRBY $24.71
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- WRBY 71.24
- CNTA 51.71
- Support Level
- WRBY $23.62
- CNTA $15.88
- Resistance Level
- WRBY $24.71
- CNTA $18.12
- Average True Range (ATR)
- WRBY 0.78
- CNTA 0.95
- MACD
- WRBY -0.08
- CNTA -0.09
- Stochastic Oscillator
- WRBY 96.66
- CNTA 44.17
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.